New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01110-18. doi: 10.1128/AAC.01110-18. Print 2019 Jan.


Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

Keywords: Acinetobacter; cefiderocol.

Publication types

  • Review

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter baumannii / drug effects*
  • Anti-Bacterial Agents / pharmacology*
  • Antibodies, Monoclonal / therapeutic use*
  • Carbapenems / therapeutic use
  • Drug Discovery
  • Drug Resistance, Multiple, Bacterial / physiology*
  • Humans
  • Microbial Sensitivity Tests
  • Phage Therapy / methods*


  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Carbapenems